SCHEMBL532982

SCHEMBL532982

O=S(=O)(c1cccc(-c2nn3cc(I)nc3s2)c1)N1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.58
LMNA P02545 2/20 0.58
ALDH1A1 P00352 7/20 0.53
MAPT P10636 3/20 0.53
HIF1A Q16665 1/20 0.53
HSD17B10 Q99714 4/20 0.51
GAA P10253 4/20 0.51
USP2 O75604 3/20 0.51
HPGD P15428 2/20 0.51
ALOX15 P16050 1/20 0.51
PIK3CA P42336 1/20 0.51
DCUN1D1 Q96GG9 2/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
RAB9A P51151 1/20 0.48
POLB P06746 1/20 0.48
KDM4E B2RXH2 4/20 0.48
TSHR P16473 3/20 0.48
RXFP1 Q9HBX9 2/20 0.48
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532637 0.87 POLB (0.49) MAPK1LMNAALDH1A1MAPTHSD17B10
SCHEMBL532646 0.80 CA12 (0.45) PIK3CA
SCHEMBL532981 0.80 PIK3CA (0.64) MAPK1LMNAALDH1A1MAPTHIF1A
SCHEMBL532184 0.77 PIK3CA (0.75) MAPK1LMNAALDH1A1MAPTHIF1A
SCHEMBL2253625 0.70 TP53 (0.69) MAPK1LMNAALDH1A1MAPTHSD17B10
SCHEMBL533516 0.70 PDE4D (0.47)
SCHEMBL532890 0.69 IKBKB (0.46) BRD4
SCHEMBL532623 0.69 DCTPP1 (0.47) ALDH1A1MAPTHSD17B10GAAHPGD
SCHEMBL14686327 0.68 ALDH1A1 (0.58) LMNAALDH1A1MAPTHIF1AHSD17B10
SCHEMBL532390 0.68 SMN1; SMN2 (0.53) ALDH1A1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414369-B1 IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) 2015-08-12 EP disclosed
US-8815918-B2 Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2014-08-26 US disclosed
US-20120094996-A1 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2012-04-19 US disclosed
EP-2414369-A1 IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2012-02-08 EP disclosed
WO-2010112874-A1 IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094996-A1 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives PIK3CA, PI4KA, PIK3CD MAPK1 191/4885LMNA 3595/4885ALDH1A1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.